Tumour-educated macrophages promote tumour progression and metastasis

Nature Reviews Cancer

Volumn 4, Issue 1, 2004, Pages 71-78

  Pollard, Jeffrey W ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FREE RADICAL; OXYGEN RADICAL;

ANGIOGENESIS; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER PREVENTION; CELL MOTILITY; EXTRACELLULAR MATRIX; HUMAN; IMMUNOMODULATION; MACROPHAGE; METASTASIS; MICROENVIRONMENT; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0347123433     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1256     Document Type: Review

References (99)

1. Lin, E. Y., Nguyen, A. V., Russell, R. G. & Pollard, J. W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193, 727-740 (2001).
2. Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860-867 (2002).
3. Coussens, L. M. Tinkle, C. L., Hanahan, D. & Werb, Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103, 481-490 (2000).
4. Iyengar, P. et al. Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization. Oncogene 22, 6408-6423 (2003)
5. Krtolica, A. et al. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc. Natl Acad. Sci. USA 98, 12072-12077 (2001).
6. Balkwill, F. & Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 357, 539-545 (2001).
7. Lin, E. Y., Gouon-Evans, V., Nguyen, A. V. & Pollard, J. W. The macrophage growth factor, CSF-1, in mammary gland development and cancer. J. Mammary Gland Biol. Neoplasia 7, 147-162 (2002).
8. Leek, R. D. & Harris, A. L. Tumor-associated macrophages in breast cancer. J. Mammary Gland Biol. Neoplasia 7, 177-189 (2002).
9. Brigati, C., Noonan, D. M., Albini, A. & Benelli, R. Tumors and inflammatory infiltrates: friends or foes? Clin. Exp. Metastasis 19, 247-258 (2002).
10. Normann, S. J. Macrophage infiltration and tumor progression, Cancer Metastasis Rev. 4, 277-291 (1985).
11. Mantovani, A. Tumor-associated macrophages in neoplastic progression: a paradigm for the in vivo function of chemokines. Lab. Invest. 71, 5-16 (1994).
12. Lingen, M. W. Role of leukocytes and endothelial cells in the development of angiogenesis in inflammation and wound healing Arch. Pathol. Lab. Med. 125, 67-71 (2001)
13. Nathan, C. Points of control in inflammation. Nature 420, 846-852 (2002).
14. Bingle, L., Brown, N. J. & Lewis, C. E. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 196, 254-265 (2002).
15. Nakayama, Y. et al. Relationships between tumor-associated macrophages and clinicopathological factors in patients with colorectal cancer. Anticancer Res. 22. 4291-4296 (2002).
16. Ueno, T. et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin. Cancer Res. 6, 3282-3289 (2000).
17. Saji, H. et al. Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer 92, 1085-1091 (2001).
18. Smith, H. O. et al. The role of colony-stimulating factor 1 and its receptor in the etiopathogenesis of endometrial adenocarcinoma. Clin Cancer Res. 1, 313-325 (1995).
19. Kacinski, B. M. CSF-1 and its receptor in breast carcinomas and neoplasms of the female reproductive tract. Mol. Reprod. Dev. 46, 71-74 (1997).
20. Kacinski, B. M. CSF-1 and its receptor in ovarian, endometrial and breast cancer. Ann. Med. 27, 79-85 (1995).
21. Scholl, S. M. et al. Anti-colony-stimulating factor-1 antibody staining in primary breast adenocardromas correlates with marked inflammatory cell infiltrates and prognosis. J. Natl Cancer Inst. 86, 120-126 (1994).
22. Elgert, K., Alleva, D. & Mullins, D. Tumor-induced immune dysfunction: the macrophage connection. J. Leukoc. Biol 64, 275-290 (1998).
23. Ohm, J. E. & Carbone, D. P. VEGF as a mediator of tumor-associated immunodeficiency. Immunol. Res 23, 263-272 (2001).
24. Dunn, G. P. et al Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunol. 3, 991-998 (2002).
25. Taylor-Papadimitriou, J. et al. MUC1 and the Immunobiology of cancer. J. Mammary Gland Biol. Neoplasia 7, 209-221 (2002).
26. Gorelik, L. & Flavell, R. A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nature Med. 7, 1118-1122 (2001).
27. Chong, H., Vodovotz, Y., Cox, G. W. & Barcellos-Hoff, M. H. Immunocytochemical localization of latent transforming growth factor-β activation by stimulated macrophages. J. Cell Physiol. 178, 275-283 (1999).
28. + progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 92, 4778-4791 (1998)
29. Menetrier-Caux, C. et al. IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells. Cancer Res. 611, 3096-3104 (2001).
30. Boggio, K. et al. Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice. Cancer Res. 60, 359-364 (2000).
31. Nanni, P. et al. Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12. Int. J. Cancer 105, 384-389 (2003).
32. Dranoff, G. Cytokines in cancer pathogenesis and cancer therapy. Nature Rev. Cancer 4, 11-22 (2004).
33. Price, L. K. H., Choi, H. U., Rosenberg, L. & Stanley, E. R. The predominant form of secreted colony stimulating factor-1 is a proteoglycan J. Biol. Chem. 267, 2190-2199 (1992).
34. Jadus, M. R. et al. Macrophages kill T9 glioma tumor cells bearing the membrane isoform of macrophage colony stimulating factor through a phagocytosis-dependent pathway. J. Immunol. 160, 361-368 (1998).
35. Jadus, M. R. et al. Macrophages can recognize and kill tumor cells bearing the membrane isoform of macrophage colony-stimulating factor. Blood 87, 5232-5241 (1996).
36. Williams, C. C. et al. Membrane macrophage colony-stimulating factor on MADB106 breast cancer cells does not activate cytotoxic macrophages but immunizes rats against breast cancer. Mol. Ther. 3, 216-224 (2001).
37. Aharinejad, S. et al. Colony-stimulating factor-1 antisense treatment suppresses growth of human tumor xenografts in mice. Cancer Res. 62, 5317-5324 (2002).
38. Hiratsuka, S. et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2, 289-300 (2002).
39. Carmeliet, P. & Jain, R. K. Angiogenesis in cancer and other diseases. Nature 407, 249-257 (2000).
40. Boudreau, N. & Myers, C. Breast cancer-induced angiogenesis: multiple mechanisms and the role of the microenvironment. Breast Cancer Res. 5, 140-146 (2003).
41. Hanahan, D. & Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364 (1996).
42. Bando, H. & Toi, M. Tumor angiogenesis, macrophages, and cytokines. Adv. Exp. Med. Biol. 476, 267-284 (2000).
43. Lewis, J. S. et al. Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J. Pathol. 192, 150-158 (2000).
44. Leek, R. D. et al. Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J. Pathol. 190, 430-436 (2000).
45. Leek, R. D. et al. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 56, 4625-4629 (1996).
46. Eubank, T. D. et al. M-CSF induces vascular endothelial growth factor production and angiogenic activity from human monocytes. J. Immunol. 171, 2637-2643 (2003).
47. Barleon, B. et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor fit-1. Blood 87, 3336-3343 (1996).
48. Miles, D. W. et al. Expression of tumour necrosis factor (TNF-α) and its receptors in benign and malignant breast tissue. Int. J. Cancer 56, 777-782 (1994).
49. Eda, H. et al. Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine. Cancer Chemother. Pharmacol. 32, 333-338 (1993).
50. Leek, R. D. et al. Association of tumour necrosis factor α and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br. J. Cancer 11, 2246-2251 (1998).
51. Hildenbrand, R., Dilger I., Horlin, A. & Stutte, H. J. Urokinase and macrophages in tumour angiogenesis. Br J Cancer 72, 818-823 (1995).
52. Stacey, K. J. et al. Regulation of urokinase-type plasminogen activator gene transcription by macrophage colony-stimulating factor. Mol. Cell. Biol. 15, 3430-3441 (1995).
53. Hildenbrand, R. et al. Transforming growth factor-β stimulates urokinase expression in tumor-associated macrophages of the breast. Lab. Invest. 78, 59-71 (1998).
54. Foekens, J. A. et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res. 60, 636-643, (2000).
55. Hildenbrand, R. et al. Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry. Histochem. Cell. Biol. 110, 27-32 (1998).
56. Fox, S. B. et al. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer. J. Pathol. 195, 236-243 (2001).
57. Knoop, A. et al. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br. J. Cancer 77, 932-940 (1998).
58. Hildenbrand, R. et al. Urokinase plasminogen activator receptor (CD87) expression of tumor-associated macrophages in ductal carcinoma in situ, breast cancer, and resident macrophages of normal breast tissue. J. Leukoc. Biol. 86, 40-49 (1999).
59. Jung, Y. J. et al. IL-1β mediated up-regulation of HIF-1α via an NFκB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J. 17, 2115-2117 (2003).
60. Voronov, E. et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc. Natl Acad. Sci. USA 100, 2645-2650 (2003).
61. MacMicking, J., Xie, Q. W. & Nathan, C. Nitric oxide and macrophage function, Annu Rev Immunol. 15, 323-350 (1997).
62. Wink, D. A. et al. The multifaceted roles of nitric oxide in cancer. Carcinogenesis 19, 711-721 (1998).
63. Ellies, L. G. et al. Mammary tumor latency is increased in mice lacking the inducible nitric oxide synthase. Int. J. Cancer 106, 1-7 (2003).
64. Grimshaw, M. J., Wilson, J. L. & Balkwill, F. R. Endothelin-2 is a macrophage chemoattractant: implications for macrophage distribution in tumors. Eur. J. Immunol. 32, 2393-2400 (2002).
65. Arnott, C. H. et al. Tumour necrosis factor-α mediates tumour promotion via a PKCα- and AP-1-dependent pathway. Oncogene 21, 4728-4738 (2002).
66. Ogmundsdottir, H. M., Petursdottir, I. & Gudmundsdottir, I. Interactions between the immune system and breast cancer. Acta Oncol 34, 647-650 (1995).
67. Menard, S., Tagliabue, E., Campiglo, M. & Pupa, S. M. Role of HER2 gene overexpression in breast carcinoma. J. Cell Physiol. 182, 150-162 (2000).
68. Nicholson, S. et al. Epidermal growth factor receptor (EGFR); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br. J. Cancer 63, 146-150 (1991).
69. O'Sullivan, C., Lewis, C. E., Harris. A. L. & McGee, J. O. Secretion of epidermal growth factor by macrophges associated with breast carcinoma. Lancet 342, 872-873 (1993).
70. Wyckoff, J. B., Segall, J. E. & Condeelis, J. S. The collection of the motile population of cells from a living tumor. Cancer Res 60, 5401-5404 (2000).
71. Lin, E. Y. et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am. J. Pathol. 163, 2113-2126 (2003).
72. Maeda, H. & Akiake, T. Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Biochemistry (Mosc.) 63, 854-865 (1998).
73. Fulton, A. M., Loveless, S. E. & Heppner, G. H. Mutagenic activity of tumor-associated macrophages in Salmonella typhimurium strains TA98 and TA100. Cancer Res. 44, 4308-4311 (1984).
74. Hudson, J. D. et al. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J. Exp. Med. 190, 1375-1382 (1999).
75. Moore, R. J. et al. Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis. Nature Med. 5, 828-831 (1999).
76. Mor, G. et al. Macrophages, estrogen and the microenvironment of breast cancer. J. Steroid Biochem. Mol. Biol. 67, 403-411 (1998).
77. Mor, G. et al. Interaction of the estrogen receptors with the Fas ligand promoter in human monocytes. J. Immunol. 170, 114-122 (2003).
78. King, B. L. et al. Immunocytochemical analysis of breast cells obtained by ductal lavage. Cancer 96, 244-249 (2002).
79. Travis, R. C. & Key, T. J. Oestrogen exposure and breast cancer risk. Breast Cancer Res. 5, 239-247 (2003).
80. Ricchi, P., Zarrili, R., Di Palma, A. & Acquaviva, A. M. Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy. Br. J. Cancer 88, 803-807 (2003).
81. Ryan, B. M., Russel, M. G., Langhoiz, E. & Stockbrugger, R. W. Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow. Am. J. Gestroenterol. 98, 1682-1687 (2003).
82. Sasmono, R. et al. A macrophage colony-stimulating factor receptor-green fluorescent protein transgene is expressed throughout the mononuclear phagocyte system of the mouse. Blood 101, 1155-1163 (2003).
83. Pollard, J. W. & Stanley, E. R. Pleiotropic roles for CSF-1 in development defined by the mouse mutation osteopetrotic (op). Adv. Dev. Biochem. 4, 153-193 (1996).
84. Pollard, J. W. Role of colony-stimulating factor-1 in reproduction and development. Mol. Reprod. Dev. 46, 54-61 (1997).
85. Gouon-Evans, V., Rothenberg, M. E. & Pollard, J. W. Postnatal mammary gland development requires macrophages and eosinophils. Development 127, 2269-2282 (2000).
86. Lang, R. A. & Bishop, J. M. Macrophages are required for cell death and tissue remodeling in the developing mouse eye. Cell 74, 453-462 (1993).
87. Gouon-Evans, V., Lin, E. Y. & Pollard, J. W. Requirement of macrophages and eosinophils and their cytokines/chemokines for mammary gland development. Breast Cancer Res. 4, 155-164 (2002).
88. Kuper, H., Adami, H. O. & Trichopoulos, D. Infections as a major preventable cause of human cancer. J. Intern. Med. 248, 171-183 (2000).
89. Rosin, M. P., Anwar W. A. & Ward, A. J. Inflammation, chromosomal instability, and cancer: the schistosomiasis model. Cancer Res. 54 (Suppl.), S1929-S1933 (1994).
90. Mostafa, M. H., Sheweita, S. A. & O'Connor P. J. Relationship between schistosomiasis and bladder cancer. Clin. Microbiol. Rev. 12, 97-111 (1999).
91. Castellsague, X., Bosch, F. X. & Munoz, N. Environmental co-factors in HPV carcinogenesis. Virus Res. 89, 191-199 (2002).
92. Shacter, E. & Weitzman, S. A Chronic inflammation and cancer. Oncology (Huntingt.) 16, 217-226, 229; discussion 230-232 (2002).
93. Kornfeld, D., Ekbom, A. & Ihre, T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut 41, 522-525 (1997).
94. Sieweke, M. H., Stoker, A. W. & Bissell. M. J. Evaluation of the cocarcinogenic effect of wounding in Rous sarcoma virus tumorigenesis. Cancer Res. 49, 6419-6424 (1989).
95. Libby, P. Inflammation in atherosclerosis. Nature 420, 868-674 (2002).
96. Di Carlo, E. et al. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 97, 339-345 (2001).
97. Coussens, L. M. et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 13, 1382-1397 (1999).
98. Haghnegandar, H. et al. The tumorgenic and angiogenic effects of MGSA/ GRO proteins in melanoma. J. Leukoc. Biol. 67, 53-62 (2000).
99. Muller. A. et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56 (2001).